13F Holdings
中文EN

INBX Inhibrx Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 2007919 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY550.0%
TTM net income YoY-108.3%
TTM EPS YoY-108.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-10,386.5%
Net margin-10,773.5%
FCF margin-9,986.5%
EBITDA margin-10,195.5%

Returns

ROE-197.8%
ROA-85.6%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets94.5%
Debt / equity12.58x
Current ratio3.93x
Interest coverage-11.07x

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue2.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$1.30M$200,000$1.80M
R&D expense$113.03M$203.74M$191.64M
SG&A expense$23.30M$127.91M$29.38M
Operating income-$135.03M-$331.45M-$219.22M
Interest expense$12.20M$13.49M$31.84M
Pretax income-$140.05M$1.69B-$239.72M
Income tax$2,000$2,000$3,000
Net income-$140.06M$1.69B-$241.36M
EBITDA-$132.54M-$329.16M-$218.03M
EPS (basic)-9.04114.01-20.48
EPS (diluted)-9.04112.62-20.48
Weighted avg. shares (diluted)15.49M14.98M11.78M
Balance sheet
Cash & equivalents$124.22M$152.60M$277.92M
Current assets$132.83M$160.40M$295.36M
PP&E, net$3.73M$6.20M$6.42M
Total assets$146.48M$180.77M$307.89M
Current liabilities$33.80M$40.73M$56.31M
Long-term debt$100.56M$0$206.97M
Total debt$100.56M$0$206.97M
Total liabilities$138.49M$47.18M$264.39M
Shareholders' equity$7.99M$133.58M$43.50M
Net debt-$23.66M-$152.60M-$70.96M
Shares outstanding14.58M14.48M47.37M
Cash flow statement
Operating cash flow-$129.79M-$194.41M-$193.31M
Capital expenditure$31,000$2.60M$4.59M
Free cash flow-$129.82M-$197.01M-$197.90M
Investing cash flow-$28,000-$2.60M-$4.59M
Financing cash flow$101.45M$71.68M$201.96M
Depreciation & amortization$2.48M$2.29M$1.19M
Stock-based compensation$11.14M$58.52M$24.85M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.